Centessa Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CNTA

*Your capital is at risk

$40.50

+0 (+0%)

At Close: Jul 23, 2026

Centessa Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -98.88. In total, the insiders bought 717.36K and sold 9.96M CNTA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-98.88
● Buy	717.36K shares
● Sell	9.96M shares
14% Buy Activity Weak Positive Correlation
Sell Signal High Confidence Jun 24, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -98.88. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (14% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Zbar Brett I W Director	Director	40 000 Value: $497.2K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Kulkarni Samarth Director	Director	48 000 Value: $426.7K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Kulkarni Samarth Director	Director	208 474 Value: $1.22M
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Kulkarni Samarth Director	Director	48 000 Value: $233.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Kulkarni Samarth Director	Director	48 000 Value: $304.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Kulkarni Samarth Director	Director	40 000 Value: $497.2K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Stuckley Carol Director	Director	48 000 Value: $304.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Goyal Arjun Director	Director	48 000 Value: $426.7K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Hedley Mary Lynne Director	Director	48 000 Value: $233.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Hedley Mary Lynne Director	Director	48 000 Value: $304.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Hedley Mary Lynne Director	Director	48 000 Value: $426.7K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Hedley Mary Lynne Director	Director	208 474 Value: $1.22M
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Accardi Mario Alberto Chief Executive Officer	CEO / President	225 000 Value: $3.80M
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Accardi Mario Alberto Chief Executive Officer	CEO / President	273 000 Value: $6.88M
Jun 24, 2026 Sell	Ordinary Shares D-Return	De Rubertis Francesco Director	Director	281 162 Value: $10.7M
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Goyal Arjun Director	Director	48 000 Value: $304.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Goyal Arjun Director	Director	48 000 Value: $233.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Goyal Arjun Director	Director	64 570 Value: $1.46M
Jun 24, 2026 Sell	Ordinary Shares D-Return	Goyal Arjun Director	Director	462 585 Value: $17.6M
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Hedley Mary Lynne Director	Director	40 000 Value: $497.2K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Stuckley Carol Director	Director	48 000 Value: $233.8K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Stuckley Carol Director	Director	208 474 Value: $1.96M
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Goyal Arjun Director	Director	40 000 Value: $497.2K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Stuckley Carol Director	Director	48 000 Value: $426.7K
Jun 24, 2026 Sell	Share Option (right to buy) D-Return	Zbar Brett I W Director	Director	48 000 Value: $426.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CENTESSA PHARMACEUTICALS LIMITED

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatm...

Read Full Profile Here